1 Av. Irène Joliot-Curie
31100 Toulouse
FRANCE
SmartCatch is lifting the current locks on CTC liquid biopsy by developing a range of compact, portable, easy-to-use products adapted to use in clinical routine, in order to make CTC liquid biopsy accessible and the essential medical procedure for the diagnosis, follow-up and personalization of care in medical oncology.
Circulatingtumor cells (CTC) are cancer cells that have escaped from a tumor and migratedthrough different biofluids in the human body. They thereforecarry key information about the presence, nature, and aggressiveness of solidtumors.Analysingthem offers vital insights into genetics, immune evasion mechanisms, andmolecular pathways. This data helps oncologists in refining cancer diagnosis,prognosis, tailoring individualized therapies, and closely monitoring diseaseprogression and treatment effectiveness.
Microtechnologies encompasses the scope of new materials, structures with ultimate resolution, and sensors with ultimate sensitivity, where the micron-scale achieved by these cutting-edge technologies meets the scale of CTC.
Circulating Tumor Cells are relatively larger and less deformable than other blood cellular components. Implemented in physiological conditions and low pressure-regimes, our technology exploits these physical traits to isolate them.
The core of the innovation consists in a microengineered capture device, developed with cutting-edge technologies and advanced computational simulations, enabling a one-step physical and selective isolation of CTC from blood in physiological conditions.
Reach out to us !
We develop solutions that meet your needs.
